Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO
Okuzawa has been with the company since 1986.
Syngene Thematic ADC WP
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
FDA grants ODD status to Zai Lab’s lung cancer treatment
Samsung Biologics and LigaChem extend ADC services deal
Chugai and Araris enter $780m ADC research collaboration
FDA awards GSK breakthrough status for relapsed osteosarcoma treatment
Innovent and Roche link on lung cancer therapy development
GSK’s lung cancer therapy gains EMA PRIME designation
